ArticleEuropean journal of epidemiology2025
Sex, male origin microchimerism, and mortality in a Danish cohort.
Article in European journal of epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously demonstrated that women with detectable male cells in peripheral blood – male origin microchimerism (a presumed souvenir from pregnancy) – enjoy half the risk of all-cause mortality compared with women tested negative. However, such differences are vulnerable to confounding. Also, it is unknown whether better survival in women vs. men is confined to women testing male origin microchimerism positive. In this updated analysis, we first compared the survival of positive and negative women using prognostic score weighing to minimize potential confounding. Next, we compared the survival of women tested positive and negative for male origin microchimerism to men. Women (n = 766) and men (n = 1,000) from the Diet, Cancer, and Health cohort aged 50–64 years in 1993–1997 were followed until 2017 for all-cause mortality in national Danish registers. Based on predictors of death, we calculated prognostic scores for all women and compared mortality according to male origin microchimerism status by prognostic score weighted Cox regression adjusting for potential confounding. Next, we compared mortality across positive/negative women and men. Women who tested male origin microchimerism positive versus negative had a 50% lower mortality rate (adjusted HR = 0.50 [95% CI 0.32–0.77]). Compared with men, women who tested positive had a 51% lower mortality rate (HR = 0.49 [95% confidence interval (CI) 0.38–0.61]), whereas women who tested negative had a similar rate (HR = 0.83 [95% CI 0.63–1.09]). Women who tested positive for male origin microchimerism lived longer than their counterparts who tested negative, who appeared to have a similar survival pattern to that of men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.